skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 76  for All Library Resources

Results 1 2 3 4 next page
Refined by: Journal Title: Pr Newswire remove creation date: 1997 To 2004 remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research
Material Type:
Newspaper Article
Add to My Research

Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research

PR newswire, 1997-11-20, p.1120

COPYRIGHT 1997 PR Newswire Association LLC

Digital Resources/Online E-Resources

2
Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research
Material Type:
Newspaper Article
Add to My Research

Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research

PR newswire, 1997-11-20, p.1120

COPYRIGHT 1997 PR Newswire Association LLC

Digital Resources/Online E-Resources

3
Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research
Material Type:
Newspaper Article
Add to My Research

Hoechst Marion Roussel Commits $1.5 Million to Aetna's Quality Care Research Fund for Outcomes Research

PR newswire, 1997-11-20, p.1120

COPYRIGHT 1997 PR Newswire Association LLC

Digital Resources/Online E-Resources

4
Onyx Pharmaceuticals Announces Exercise of Over-Allotment Option for Public Offering
Material Type:
Newspaper Article
Add to My Research

Onyx Pharmaceuticals Announces Exercise of Over-Allotment Option for Public Offering

PR newswire, 2000-10-21, p.3868-3868

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

5
Entremed, Inc. Announces Commencement of Phase I Clinical Trial Of Angiostatin Protein in Combination With Radiation Therapy
Material Type:
Newspaper Article
Add to My Research

Entremed, Inc. Announces Commencement of Phase I Clinical Trial Of Angiostatin Protein in Combination With Radiation Therapy

PR newswire, 2000-07-06, p.3471-3471

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

6
Onyx Announces New Members of Board of Directors
Material Type:
Newspaper Article
Add to My Research

Onyx Announces New Members of Board of Directors

PR newswire, 2000-06-13

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

7
CI-1042 (ONYX-015) May Have Potential Against Cancer in Variety of Tumor Types
Material Type:
Newspaper Article
Add to My Research

CI-1042 (ONYX-015) May Have Potential Against Cancer in Variety of Tumor Types

PR newswire, 2000-05-24, p.6013-6013

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

8
Onyx Pharmaceuticals Announces $18 Million Private Placement, New Management Appointments
Material Type:
Newspaper Article
Add to My Research

Onyx Pharmaceuticals Announces $18 Million Private Placement, New Management Appointments

PR newswire, 2000-01-19, p.4569-4569

COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

9
FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer
Material Type:
Newspaper Article
Add to My Research

FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer

PR newswire, 1999-09-07, p.1806

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

10
FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer
Material Type:
Newspaper Article
Add to My Research

FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer

PR newswire, 1999-09-07, p.1806

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

11
FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer
Material Type:
Newspaper Article
Add to My Research

FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer

PR newswire, 1999-09-07, p.1806

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

12
Warner Chilcott Management Increases Stake in Company
Material Type:
Newspaper Article
Add to My Research

Warner Chilcott Management Increases Stake in Company

PR newswire, 1999-01-08, p.0838

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

13
Warner Chilcott Management Increases Stake in Company
Material Type:
Newspaper Article
Add to My Research

Warner Chilcott Management Increases Stake in Company

PR newswire, 1999-01-08, p.0838

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

14
Warner Chilcott Management Increases Stake in Company
Material Type:
Newspaper Article
Add to My Research

Warner Chilcott Management Increases Stake in Company

PR newswire, 1999-01-08, p.0838

COPYRIGHT 1999 PR Newswire Association LLC

Digital Resources/Online E-Resources

15
Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock
Material Type:
Newspaper Article
Add to My Research

Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock

PR newswire, 1998-03-10, p.310

COPYRIGHT 1998 PR Newswire Association LLC

Digital Resources/Online E-Resources

16
Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock
Material Type:
Newspaper Article
Add to My Research

Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock

PR newswire, 1998-03-10, p.310

COPYRIGHT 1998 PR Newswire Association LLC

Digital Resources/Online E-Resources

17
Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock
Material Type:
Newspaper Article
Add to My Research

Affymetrix Announces Definitive Agreement to Sell $50 Million of Series AA Preferred Stock

PR newswire, 1998-03-10, p.310

COPYRIGHT 1998 PR Newswire Association LLC

Digital Resources/Online E-Resources

18
Immunicon Announces Agreement With Ortho-Clinical Diagnostics, Inc.; Companies to Collaborate on Screening and Diagnostic Products for Cancer
Material Type:
Newspaper Article
Add to My Research

Immunicon Announces Agreement With Ortho-Clinical Diagnostics, Inc.; Companies to Collaborate on Screening and Diagnostic Products for Cancer

PR newswire, 2000-09-11

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

19
Leonard E. Post, Former Parke-Davis V.P. Biologicals, Joins Onyx Pharmaceuticals as Senior Vice President, Research Development
Material Type:
Newspaper Article
Add to My Research

Leonard E. Post, Former Parke-Davis V.P. Biologicals, Joins Onyx Pharmaceuticals as Senior Vice President, Research Development

PR newswire, 2000-08-03

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

20
New Agreements Provide Onyx With Novel Technology and Genes for Developing A Range of Anticancer Therapies
Material Type:
Newspaper Article
Add to My Research

New Agreements Provide Onyx With Novel Technology and Genes for Developing A Range of Anticancer Therapies

PR newswire, 2000-08-02

COPYRIGHT 2000 PR Newswire Association LLC ;COPYRIGHT 2000 PR Newswire Association LLC

Digital Resources/Online E-Resources

Results 1 - 20 of 76  for All Library Resources

Results 1 2 3 4 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To

Searching Remote Databases, Please Wait